CAR-T cell therapy for advanced NKG2DL-positive solid tumors
Part of Cancer clinical trials.
This trial tests a new type of immune cell therapy (NKG2D CAR-T cells) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if these specially engineered cells can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor (like ovarian, bile duct, or colorectal cancer) that is advanced and has not gotten better with standard treatments, or you cannot tolerate those treatments.
- You are between 18 and 70 years old.
- A recent biopsy shows your tumor has a marker called NKG2DL (a protein on the surface of some cancer cells).
- Your overall health is good enough for this treatment (you can do your daily activities with little help, and your organs work well).
- You have a vein that can be used to collect your blood cells for making the CAR-T cells.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy called KD-496, which is a CAR T-cell designed to attack tumors that have NKG2DL or CLDN18.2 markers. It may be an option for people with advanced solid tumors (commonly stomach or pancreatic cancer) who have tried at least two prior treatments.
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
This trial tests a new CAR T-cell therapy made from your own immune cells to treat advanced cancers that have not responded to other treatments. It may be an option if your tumor has a specific target and you are otherwise healthy enough.
This trial tests a new type of immune cell therapy (CAR-NKT cells) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Hear when a new Safety Issues trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.